Skip to main content
    O

    Organon & Co (OGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $13.91
    +0.01 (+0.07%)

    Market Cap: $3.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organon & Co (OGN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    Organon reported revenue of $6.22B for the fiscal year ended Dec 31, 2025, down 2.9% from the year before. That year, net income was $187.00M with a net margin of 3.0%, operating cash flow was $700.00M and free cash flow was $538.00M. The quarter ended Sep 30, 2026 had revenue of $1.57B and net income of $164.00M.

    Revenue and Margins

    The operating margin was 13.3% in the fiscal year ended Dec 2025, the lowest of the 9 years shown. Over the 8 years to Dec 2025, revenue fell from $10.50B, a compound annual decline of 6.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$6.22B-2.9%53.3%13.3%3.0%
    Dec 2024$6.40B+2.2%58.0%21.5%13.5%
    Dec 2023$6.26B+1.4%59.8%20.1%16.3%
    Dec 2022$6.17B-2.1%62.8%25.4%14.9%
    Dec 2021$6.30B-3.5%61.9%28.4%21.4%
    Dec 2020$6.53B-16.0%67.6%42.7%33.1%
    Dec 2019$7.78B-20.5%70.8%48.4%41.4%
    Dec 2018$9.78B-6.9%52.0%27.7%22.0%
    Dec 2017$10.50BN/A56.3%31.2%17.2%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 78.4% from the year before. In the quarter ended Sep 2026, net income rose 2.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$6.22B$6.40B$6.26B$6.17B$6.30B$6.53B$7.78B$9.78B$10.50B
    Cost of revenue$2.90B$2.69B$2.52B$2.29B$2.40B$2.12B$2.27B$4.69B$4.59B
    Gross profit$3.31B$3.71B$3.75B$3.88B$3.90B$4.41B$5.50B$5.08B$5.91B
    Research and development$372.00M$550.00M$536.00M$578.00M$443.00M$210.00M$220.00M$365.00M$355.00M
    Operating income$824.00M$1.37B$1.26B$1.57B$1.79B$2.79B$3.76B$2.71B$3.27B
    Net income$187.00M$864.00M$1.02B$917.00M$1.35B$2.16B$3.22B$2.15B$1.80B
    EBITDA$1.29B$1.60B$1.44B$1.76B$1.98B$2.89B$4.03B$4.38B$5.08B
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.57B$1.56B$1.46B$1.51B$1.60B$1.59B$1.51B$1.59B$1.58B$1.61B$1.62B$1.60B
    Gross profit$869.00M$847.00M$783.00M$741.00M$857.00M$874.00M$841.00M$896.00M$923.00M$939.00M$957.00M$915.00M
    Operating income$365.00M$322.00M$235.00M-$91.00M$358.00M$324.00M$233.00M$288.00M$339.00M$371.00M$376.00M$254.00M
    Net income$164.00M$108.00M$146.00M-$205.00M$160.00M$145.00M$87.00M$109.00M$359.00M$195.00M$201.00M$546.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $8.64B exceeded cash and equivalents by $8.07B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$12.87B$13.10B$12.06B$10.96B$10.68B$10.11B$10.55B$10.49BN/A
    Current assets$4.35B$4.35B$4.51B$3.93B$3.76B$3.57B$3.96B$3.71BN/A
    Cash and equivalents$574.00M$675.00M$693.00M$706.00M$737.00M$12.00M$319.00M$244.00MN/A
    Total liabilities$12.12B$12.63B$12.13B$11.85B$12.19B$4.62B$3.51B$4.15BN/A
    Short-term debt$16.00M$20.00M$9.00M$8.00M$9.00M$0$48.00M-$207.00MN/A
    Long-term debt$8.63B$8.86B$8.75B$8.90B$9.13B$0$70.00M$34.00MN/A
    Shareholder equity$752.00M$472.00M-$70.00M-$892.00M-$1.51B$5.49B$7.04B$6.35BN/A
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.40B$13.18B$13.00B$12.87B$13.55B$13.50B$13.16B$13.10B$12.75B$12.15B$11.89B$12.06B
    Total liabilities$12.21B$12.17B$12.09B$12.12B$12.65B$12.77B$12.61B$12.63B$12.26B$12.01B$11.84B$12.13B
    Cash and equivalents$1.46B$1.13B$1.12B$574.00M$672.00M$599.00M$547.00M$675.00M$763.00M$704.00M$575.00M$693.00M
    Shareholder equity$1.19B$1.01B$903.00M$752.00M$906.00M$733.00M$542.00M$472.00M$493.00M$144.00M$48.00M-$70.00M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 76.9% of operating cash flow. Dividends came to 16.4% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow$700.00M$939.00M$799.00M$858.00M$2.16B$2.28B$3.02B$3.69B$3.42B
    Capital expenditures$162.00M$175.00M$251.00M$196.00M$192.00M$255.00M$92.00M$101.00M$86.00M
    Free cash flow$538.00M$764.00M$548.00M$662.00M$1.97B$2.03B$2.93B$3.59B$3.33B
    Dividends paid$88.00M$297.00M$294.00M$290.00M$145.00M$0$0$145.00MN/A
    Investing cash flow-$390.00M-$513.00M-$260.00M-$420.00M-$481.00M-$250.00M-$88.00M-$69.00M-$56.00M
    Financing cash flow-$561.00M-$368.00M-$569.00M-$433.00M-$977.00M-$2.02B-$2.93B-$4.16B-$3.37B
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$370.00M$107.00M$225.00M$141.00M$264.00M$220.00M$75.00M$390.00M$141.00M$332.00M$76.00M$397.00M
    Capital expenditures$44.00M$42.00M$37.00M$45.00M$46.00M$39.00M$32.00M$55.00M$42.00M$32.00M$46.00M$79.00M
    Free cash flow$326.00M$65.00M$188.00M$96.00M$218.00M$181.00M$43.00M$335.00M$99.00M$300.00M$30.00M$318.00M
    Last 12 quarters

    Frequently Asked Questions About OGN

    What is Organon's annual revenue?

    Organon reported revenue of $6.22B for the fiscal year ended Dec 31, 2025.

    How fast is Organon's revenue growing?

    Revenue was down 2.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.2%.

    Is Organon profitable?

    Yes. Organon reported net income of $187.00M for the fiscal year ended Dec 31, 2025, with a net margin of 3.0%.

    How much free cash flow does OGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $700.00M minus capital expenditures of $162.00M produced free cash flow of $538.00M.

    How much debt does Organon have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $8.63B, short-term debt of $16.00M and cash and equivalents of $574.00M.